先健科技Cinenses™肺減容回力圈系統歐洲臨牀試驗完成入組
格隆匯5月12日丨領先的心腦血管及外周血管微創介入醫療器械企業先健科技(1302.HK)宣佈,旗下控股子公司先健呼吸科技自主研發的Cinenses™肺減容回力圈系統已順利完成歐洲臨牀試驗入組,標誌着先健科技已堅實地邁入呼吸疾病介入診斷治療這一廣闊新領域。Cinenses™肺減容回力圈系統為國內首創,技術水平國際領先。該產品的適用範圍廣泛,可用於所有嚴重肺氣腫患者,尤其針對存在側枝通氣、過度膨脹以及生活質量不佳的重度肺氣腫患者,其可彌補現有技術無法治療的難點,顯著提升患者的生活質量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.